Related to Vertex to Receive $155M Tied to HCV Drug’s Clinical and Commercial Success in Europe

• Genotyping HCV Patients for HLA-C and IL28B Improves Ability to Predict Treatment Response
  
• Roche Buys HCV Therapeutics Firm Anadys for $230M in Cash
  
• FDA Green-Lights Janssen's Anticoagulant for Reducing Stroke/Embolism in Nonvalvular AF Patients
  
• Phase III Study Demonstrates Benefits of Janssen’s Xarelto in Acute Coronary Syndrome
  
• Gilead Ponies Up $11B to Purchase Pharmasset
  
• BMS, Tibotec to Combine Anti-HCV Candidates in Phase II Trial
  
• Roche Gets CE Clearance for Two HCV Molecular Diagnostics
  
• New Target and FDA-Approved Cholesterol-Lowering Drug Identified for HCV Therapy
  
• BMS to Buy Anti-Infectives Firm Inhibitex for $2.5B in Cash
  
• Janssen Starts Open Innovation Lab in San Diego
  
• BioLineRx Nabs Rights to Genoscience’s Early-Stage HCV Therapy
  
• FDA Sanctions Vertex’ Kalydeco for Treating Cystic Fibrosis Caused by G551D Mutations
  
• BioLineRx Licenses Second Anti-HCV Candidate from Genoscience
  
• Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors
  
• Janssen Reports Positive Phase III Data for Chronic Diabetic Peripheral Neuropathy Analgesic
  
• Janssen’s Stelara Improves Active Psoriatic Arthritis in Phase III Study
  
• Firms Report Phase III Data at 72nd American Diabetes Association Congress
  
• FDA Fails to Back Janssen, Bayer’s Xarelto for Acute Coronary Syndrome
  
• Janssen Buys CorImmun for Clinical-Stage Heart Failure Drug
  
• CureBeta Snags $8M Up Front for Beta-Cell Regeneration Candidates